|
| related topics |
| {customer, product, revenue} |
| {stock, price, share} |
| {product, liability, claim} |
| {stock, price, operating} |
| {personnel, key, retain} |
| {property, intellectual, protect} |
| {acquisition, growth, future} |
| {product, market, service} |
| {interest, director, officer} |
| {cost, regulation, environmental} |
|
|
Because of our recent development status and the nature of our business, our securities are highly speculative.
We have limited operating history primarily involved in product development, and we have not generated any commercial revenues to date.
If we are unable to obtain significant additional financing as needed, our business plan most likely will result in failure.
Our ability to generate future revenues will depend upon a number of factors, some of which are beyond our control.
We have limited experience in producing healthcare products.
We will depend upon a limited number of outside suppliers.
We will be very dependent upon our distribution network of sales representatives.
We will face significant challenges in obtaining market acceptance of PuraMed products and establishing our PuraMed brand.
Our business is substantially dependent upon our current employees and our ability to attract, recruit and retain additional key employees.
Introduction of new products by our competitors could reduce the demand for our products materially.
Our business depends substantially on our ability to protect our intellectual property rights, and any material failure to protect these rights would be harmful to us.
We must comply with many governmental regulations relating to our products
We do not intend to pay any cash dividends on our common stock.
The price of our common stock in any active trading market that may develop may be volatile and fluctuate significantly.
Our current management team owns 46% of our outstanding stock and thus most likely controls our company and they may make material decisions with which other shareholders disagree.
Additional shares of our authorized capital stock which are issued in the future will decrease equity ownership percentages of existing shareholders, could also be dilutive to existing shareholders, and could delay or prevent a change of control of our company.
Full 10-K form ▸
|
|
| related documents |
| 862861--3/31/2006--APPLIANCE_RECYCLING_CENTERS_OF_AMERICA_INC_/MN |
| 885307--11/24/2006--JEWETT_CAMERON_TRADING_CO_LTD |
| 885307--11/3/2010--JEWETT_CAMERON_TRADING_CO_LTD |
| 885307--11/12/2008--JEWETT_CAMERON_TRADING_CO_LTD |
| 885307--10/30/2007--JEWETT_CAMERON_TRADING_CO_LTD |
| 1019787--4/13/2009--PURADYN_FILTER_TECHNOLOGIES_INC |
| 1324759--3/31/2010--Cereplast_Inc |
| 5768--6/9/2006--AMERICAN_SCIENCE_&_ENGINEERING_INC |
| 1005286--7/27/2006--LANDEC_CORP_\CA\ |
| 1005286--7/27/2007--LANDEC_CORP_\CA\ |
| 720671--7/16/2008--HALIFAX_CORP_OF_VIRGINIA |
| 857953--4/11/2006--JMAR_TECHNOLOGIES_INC |
| 87050--1/29/2007--SBE_INC |
| 720671--7/10/2007--HALIFAX_CORP |
| 1005286--8/8/2008--LANDEC_CORP_\CA\ |
| 1068874--10/15/2007--IMPLANT_SCIENCES_CORP |
| 1005286--8/4/2009--LANDEC_CORP_\CA\ |
| 882873--9/17/2010--UROLOGIX_INC |
| 869986--6/29/2006--ADVANCED_PHOTONIX_INC |
| 749660--3/23/2010--ICAD_INC |
| 5768--6/13/2008--AMERICAN_SCIENCE_&_ENGINEERING_INC |
| 867840--9/26/2008--PRECISION_OPTICS_CORPORATION_INC |
| 5768--6/15/2009--AMERICAN_SCIENCE_&_ENGINEERING_INC |
| 74046--10/10/2008--OIL_DRI_CORP_OF_AMERICA |
| 74046--10/9/2009--OIL_DRI_CORP_OF_AMERICA |
| 1311538--6/29/2009--Castle_Brands_Inc |
| 74046--10/10/2007--OIL_DRI_CORP_OF_AMERICA |
| 74046--10/20/2006--OIL_DRI_CORPORATION_OF_AMERICA |
| 887226--9/28/2007--PERCEPTRON_INC/MI |
| 715073--11/26/2008--WEGENER_CORP |
|